Montreal, Canada

John Hanrahan

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: John Hanrahan: Innovator in Pharmaceutical Treatments

Introduction

John Hanrahan is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of respiratory diseases and male infertility. With a total of 2 patents, his work is paving the way for innovative therapeutic solutions.

Latest Patents

Hanrahan's latest patents focus on a compound designed to treat or prevent various diseases, including cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, and more. The compound, identified as 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one, modulates CFTR activity to provide therapeutic benefits. Additionally, his inventions include compositions that combine this compound with leukotriene receptor antagonists and CFTR potentiators or correctors, enhancing their effectiveness in treating these conditions.

Career Highlights

John Hanrahan is currently associated with Verona Pharma Plc, where he continues to develop innovative treatments. His work is characterized by a commitment to improving patient outcomes through scientific research and development.

Collaborations

Hanrahan collaborates with esteemed colleagues, including Katharine Abbott-Banner and David Thomas, to advance his research and innovations in the pharmaceutical field.

Conclusion

John Hanrahan's contributions to pharmaceutical innovations demonstrate his dedication to addressing critical health issues. His work not only showcases his inventive spirit but also highlights the importance of collaboration in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…